Puma Biotechnology's (NASDAQ:PBYI) Strong Earnings Are Of Good Quality

Simply Wall StNov 20 13:26 ET

H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsNov 20 11:32 ET · Ratings

Buy Rating Reiterated for Puma Biotechnology Amid Promising Phase 2 Trial and Strategic FDA Engagement

TipRanksNov 20 11:15 ET · Ratings

Puma Biotechnology Launches Mid-Stage Trial of Alisertib to Treat Breast Cancer

MT NewswiresNov 20 09:40 ET

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

BenzingaNov 20 08:58 ET

Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Yahoo FinanceNov 20 08:57 ET